Agilent Technologies Inc. (NYSE: A) today announced professors , and ., as recipients of an Agilent Thought Leader Award. Both scientists are being recognized for their joint contributions to the field of CAR T-cell mediated cancer immunotherapy, having codeveloped tisagenlecleucel (Kymriah?), the first cell and gene therapy product approved by the US FDA.
The award will focus on defining standards for the design, validation, and manufacturing of cell-based cancer therapeutics. Combining metabolomic and cell-based tools with more efficient CRISPR-based engineering of T-cells will allow labs to validate and maintain quality control downstream in development and manufacturing.
Agilent will provide modified gRNAs and oligonucleotide libraries to optimize the engineering of patient T-cells. Agilent will also provide instruments including an xCELLigence RTCA eSight, a NovoCyte Quanteon Flow Cytometer, a 6546 LC/Q-TOF Mass Spectrometer, and a 2100 Bioanalyzer system, which will work in concert with cell engineering advances to enable the development of protocols and workflows for characterization and selection of the best approaches to T-cell engineering.
“It’s an honor to be chosen for an Agilent Thought Leader Award. Partnering with Agilent will help strengthen our research in areas with a critical impact on cancer treatment,” said Dr. June.
The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the Agilent Thought Leader Award webpage.